<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04988256</url>
  </required_header>
  <id_info>
    <org_study_id>HS-20-00118</org_study_id>
    <nct_id>NCT04988256</nct_id>
  </id_info>
  <brief_title>Cyclosporine vs Steroids in DRESS</brief_title>
  <official_title>A Randomized Controlled Pilot Trial of Cyclosporine vs Steroids in DRESS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Southern California</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Current treatments for patients with drug reaction with eosinophilia and systemic symptoms&#xD;
      (DRESS) include supportive care, steroids and cyclosporine. No randomized controlled trial&#xD;
      (RCT) exists in comparing these treatments and all available literature comes in the form of&#xD;
      case reports and case series. These two treatments are considered standard of care and this&#xD;
      trial seeks only to compare outcomes of DRESS between these two therapies. No additional&#xD;
      labs, therapies or procedures will be used apart from those that are routinely done for&#xD;
      patients with this diagnosis.&#xD;
&#xD;
      This will be a pilot study to determine efficacy of the two therapies with particular&#xD;
      endpoints in mind so that the investigators can study the safety of these two therapies in&#xD;
      patients with DRESS.&#xD;
&#xD;
      Data suggests a potential benefit for adults with DRESS using either steroids or cyclosporine&#xD;
      but the investigators are seeking a comparison of efficacy of these two therapies. The study&#xD;
      population will include adults with a Registry of Severe Cutaneous Adverse Reaction&#xD;
      (RegiSCAR) score of greater than 4 (i.e. a likely diagnosis of DRESS). The investigators will&#xD;
      exclude patients with sepsis, active Hepatitis B or C, active tuberculosis, a documented&#xD;
      allergy to steroids or cyclosporine, and patients with an estimated glomerular filtration&#xD;
      rate (eGFR) &lt; 30 (unless on dialysis in which case the participants will be included).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Current treatments for patients with drug reaction with eosinophilia and systemic symptoms&#xD;
      (DRESS) include supportive care, steroids, cyclosporine and to a lesser extent, intravenous&#xD;
      immunoglobulin (IVIG). Regarding IVIG, a recent case series suggests no improved benefit in&#xD;
      adults. No randomized controlled trial (RCT) exists in comparing these treatments and all&#xD;
      available literature comes in the form of case reports and case series. These two treatments&#xD;
      are considered standard of care and this trial seeks only to compare outcomes of DRESS&#xD;
      between these two therapies. No additional labs, therapies or procedures will be used apart&#xD;
      from those that are routinely done for patients with this diagnosis.&#xD;
&#xD;
      This will be a pilot study to determine efficacy of the two therapies with particular&#xD;
      endpoints in mind so that the investigators can study the safety of these two therapies in&#xD;
      patients with DRESS. Hopefully, this study will allow the investigators to better power a&#xD;
      full prospective trial in the future.&#xD;
&#xD;
      This is a potentially life-threatening severe cutaneous adverse reaction (SCAR) with&#xD;
      significant potential morbidity. Data suggests a potential benefit for adults with DRESS&#xD;
      using either steroids or cyclosporine but the investigators are seeking a comparison of&#xD;
      efficacy of these two therapies. The study population will include adults with a Registry of&#xD;
      Severe Cutaneous Adverse Reaction (RegiSCAR) score of greater than 4 (i.e. a likely diagnosis&#xD;
      of DRESS). The investigators will exclude patients with sepsis, active Hepatitis B or C,&#xD;
      active tuberculosis, a documented allergy to steroids or cyclosporine, and patients with an&#xD;
      estimated glomerular filtration rate (eGFR) &lt; 30 (unless on dialysis in which case the&#xD;
      participants will be included).&#xD;
&#xD;
      Participants will be randomized using a randomization protocol at all sites. Primary&#xD;
      endpoints will include percentage of participants with complete or near complete resolution&#xD;
      of organ involvement as well as erythema resolution at day 7 and day 30.&#xD;
&#xD;
      Secondary endpoints will be:&#xD;
&#xD;
        1. fever presence, resolution of facial edema, resolution of pruritus, lymphadenopathy,&#xD;
           eosinophil count at days 7 and 30&#xD;
&#xD;
        2. days of hospitalization&#xD;
&#xD;
        3. mortality at days 7, 30 and 90&#xD;
&#xD;
        4. viral reactivation at days 30, 60 and 90&#xD;
&#xD;
        5. those with autoimmune development by day 30 and day 90&#xD;
&#xD;
        6. 30 day re-admission rate.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Anticipated">July 31, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2023</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with complete or near complete resolution of organ involvement at day 30, on steroid therapy and cyclosporine therapy</measure>
    <time_frame>Day 7</time_frame>
    <description>Measured by the following quantitative metrics:&#xD;
Creatinine within 1.25x of baseline or upper limit of normal, whichever is higher&#xD;
Aspartate Aminotransferase (AST) within 1.5x of baseline or upper limit of normal, whichever is higher&#xD;
Troponin-T, Creatine Kinase Myocardial Band (CK-MB), Pro B-type Natriuretic Peptide (Pro-BNP), and lipase within 1.25x of baseline or upper limit of normal, whichever is higher&#xD;
Resolution of interstitial pneumonitis on chest x-ray</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of patients with complete or near complete resolution of organ involvement at day 30, on steroid therapy and cyclosporine therapy</measure>
    <time_frame>Day 30</time_frame>
    <description>Measured by the following quantitative metrics:&#xD;
Creatinine within 1.25x of baseline or upper limit of normal, whichever is higher&#xD;
Aspartate Aminotransferase (AST) within 1.5x of baseline or upper limit of normal, whichever is higher&#xD;
Troponin-T, Creatine Kinase Myocardial Band (CK-MB), Pro B-type Natriuretic Peptide (Pro-BNP), and lipase within 1.25x of baseline or upper limit of normal, whichever is higher&#xD;
Resolution of interstitial pneumonitis on chest x-ray</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of patients with complete or near complete resolution of erythema at day 7, on steroid therapy and cyclosporine therapy</measure>
    <time_frame>Day 7</time_frame>
    <description>Clinical measurement of erythema</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of patients with complete or near complete resolution of erythema at day 30, on steroid therapy and cyclosporine therapy</measure>
    <time_frame>Day 30</time_frame>
    <description>Clinical measurement of erythema</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with resolution of fever</measure>
    <time_frame>Day 7</time_frame>
    <description>Less than 38 degrees Celsius for at least 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with resolution of fever</measure>
    <time_frame>Day 30</time_frame>
    <description>Less than 38 degrees Celsius for at least 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with resolution of facial edema</measure>
    <time_frame>Day 7</time_frame>
    <description>Clinical resolution of edema for at least 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with resolution of facial edema</measure>
    <time_frame>Day 30</time_frame>
    <description>Clinical resolution of edema for at least 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with resolution of pruritus</measure>
    <time_frame>Day 7</time_frame>
    <description>Resolution for at least 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with resolution of pruritus</measure>
    <time_frame>Day 30</time_frame>
    <description>Resolution for at least 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with resolution of lymphadenopathy</measure>
    <time_frame>Day 7</time_frame>
    <description>Clinical resolution of lymphadenopathy for at least 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with resolution of lymphadenopathy</measure>
    <time_frame>Day 30</time_frame>
    <description>Clinical resolution of lymphadenopathy for at least 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute eosinophil proportion compared to peak value</measure>
    <time_frame>Day 7</time_frame>
    <description>Proportion of absolute eosinophils</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute eosinophil proportion compared to peak value</measure>
    <time_frame>Day 30</time_frame>
    <description>Proportion of absolute eosinophils</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients with autoimmune disease development</measure>
    <time_frame>Day 30</time_frame>
    <description>Measured by titers of autoimmune markers (Antinuclear Antibody (ANA), Thyroid Stimulating Hormone (TSH)) compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients with autoimmune disease development</measure>
    <time_frame>Day 90</time_frame>
    <description>Measured by titers of autoimmune markers (Antinuclear Antibody (ANA), Thyroid Stimulating Hormone (TSH)) compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total days of hospitalization after initial dermatology consult</measure>
    <time_frame>0-120 days</time_frame>
    <description>Number of days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral reactivation</measure>
    <time_frame>Day 30</time_frame>
    <description>Measured by titers of Human Herpesvirus 6 (HHV6), Cytomegalovirus (CMV), and Epstein-Barr Virus (EBV)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral reactivation</measure>
    <time_frame>Day 60</time_frame>
    <description>Measured by titers of Human Herpesvirus 6 (HHV6), Cytomegalovirus (CMV), and Epstein-Barr Virus (EBV)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral reactivation</measure>
    <time_frame>Day 90</time_frame>
    <description>Measured by titers of Human Herpesvirus 6 (HHV6), Cytomegalovirus (CMV), and Epstein-Barr Virus (EBV)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>Day 7</time_frame>
    <description>Proportion of patient mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>Day 30</time_frame>
    <description>Proportion of patient mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>Day 90</time_frame>
    <description>Proportion of patient mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30-day readmission rate</measure>
    <time_frame>Day 30</time_frame>
    <description>Proportion of patients re-admitted to the hospital within 30 days of discharge</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>DRESS Syndrome</condition>
  <condition>Drug-Induced Hypersensitivity Syndrome</condition>
  <arm_group>
    <arm_group_label>Cyclosporine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All Patients start with 5 mg/kg/day (3 mg/kg/day if renal impairment) PO divided bid for 7 days (or IV if patient is NPO)&#xD;
If complete resolution, stop cyclosporine and monitor closely for relapse&#xD;
a. If patient relapses, give 5 (3 if renal impairment) mg/kg/day PO divided bid PO for 7 days&#xD;
i. If down-trending, start oral taper regimen&#xD;
ii. If not down-trending, switch to steroid arm&#xD;
If &gt;25% improvement and labs are down-trending, start the oral taper regimen.&#xD;
If 0-25% improvement, give 5 (3 if renal impairment) mg/kg/day PO divided bid for 3 days&#xD;
If down-trending, start oral taper regimen&#xD;
If not down-trending, switch to steroid arm&#xD;
If no improvement or up-trending labs at 7 days, switch to steroid arm&#xD;
Oral Taper Regimen set as 3 mg/kg PO divided bid for 14 days, then 2 mg/kg PO divided bid for 20 days. If renal impairment, oral taper regimen set as 2 mg/kg PO divided bid for 14 days, then 1 mg/kg PO divided bid for 20 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Corticosteroids</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All Patients start with 500 mg IV Methylprednisolone for 3 days&#xD;
1. If &gt;25% improvement (must be &gt;25% in all involved organs), start the taper regimen 2. If 0-25% improvement (in â‰¥1 involved internal organ), give 500 mg IV Methylprednisolone for 4 days&#xD;
If no improvement, switch to cyclosporine arm of treatment&#xD;
If 0-25% improvement, give 500 mg IV Methylprednisolone for 3 days&#xD;
i. If labs are down-trending, start the taper regimen&#xD;
ii. If labs are not down-trending, switch to cyclosporine arm of the study&#xD;
c. If &gt;25% improvement, start the taper regimen&#xD;
Taper Regimen set as:&#xD;
125 mg IV Methylprednisolone x3 days&#xD;
1.2 mg/kg PO prednisone x1 week&#xD;
1 mg/kg PO prednisone x1 week&#xD;
0.8 mg/kg PO prednisone x1 week&#xD;
0.6 mg/kg PO prednisone x1 week&#xD;
0.4 mg/kg PO prednisone x1 week&#xD;
0.2 mg/kg PO prednisone x1 week&#xD;
0.1 mg/kg PO prednisone x1 week&#xD;
0.05 mg/kg PO prednisone x1 week</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine</intervention_name>
    <description>Patients randomized to cyclosporine will be treated as mentioned under &quot;Arm/Group Description&quot;</description>
    <arm_group_label>Cyclosporine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone and Prednisone</intervention_name>
    <description>All patients randomized to steroids will initially be treated with IV methylprednisolone and eventually started on an oral prednisone taper.</description>
    <arm_group_label>Corticosteroids</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults with a RegiSCAR score of greater than 4 (i.e a likely diagnosis of DRESS)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active sepsis&#xD;
&#xD;
          -  Active hepatitis B or C&#xD;
&#xD;
          -  Active tuberculosis&#xD;
&#xD;
          -  Documented allergy to steroids or cyclosporine&#xD;
&#xD;
          -  Estimated glomerular filtration rate (eGFR) &lt; 30 (unless on dialysis, in which case&#xD;
             they will be included)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>USC</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 24, 2021</study_first_submitted>
  <study_first_submitted_qc>July 31, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2021</study_first_posted>
  <last_update_submitted>July 31, 2021</last_update_submitted>
  <last_update_submitted_qc>July 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Southern California</investigator_affiliation>
    <investigator_full_name>Scott Worswick</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Drug Hypersensitivity Syndrome</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

